Conference Coverage

Adjuvant sunitinib offers DFS edge in high-risk RCC

Publish date: October 14, 2016

 

AT ESMO 2016

Pages

Recommended Reading

Drug combo shows promise for non–clear cell renal cell carcinoma
MDedge Hematology and Oncology
New anticancer drugs linked to increased costs, life expectancy
MDedge Hematology and Oncology
FDA modifies dosage regimen for nivolumab
MDedge Hematology and Oncology
No link between vasectomy, prostate cancer in U.S. cohort
MDedge Hematology and Oncology
10-year follow-up: Localized prostate cancer treatments offer similar efficacy
MDedge Hematology and Oncology
Evaluation of a policy of lymph node retrieval for colon cancer specimens: a quality improvement opportunity
MDedge Hematology and Oncology
A positive attitude in prostate cancer challenges: finding hope and optimism
MDedge Hematology and Oncology
Prostate cancer recurrence rates low with SBRT
MDedge Hematology and Oncology
Hypofractionated RT safe, convenient in low-risk prostate cancer
MDedge Hematology and Oncology
In favorable intermediate-risk prostate cancer, brachytherapy alone suffices
MDedge Hematology and Oncology